These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 14970111)

  • 1. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study.
    Sliwa K; Woodiwiss A; Kone VN; Candy G; Badenhorst D; Norton G; Zambakides C; Peters F; Essop R
    Circulation; 2004 Feb; 109(6):750-5. PubMed ID: 14970111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy.
    Sliwa K; Woodiwiss A; Candy G; Badenhorst D; Libhaber C; Norton G; Skudicky D; Sareli P
    Am J Cardiol; 2002 Nov; 90(10):1118-22. PubMed ID: 12423714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy.
    Sliwa K; Skudicky D; Candy G; Wisenbaugh T; Sareli P
    Lancet; 1998 Apr; 351(9109):1091-3. PubMed ID: 9660578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms.
    Bahrmann P; Hengst UM; Richartz BM; Figulla HR
    Eur J Heart Fail; 2004 Mar; 6(2):195-201. PubMed ID: 14984727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study.
    Skudicky D; Bergemann A; Sliwa K; Candy G; Sareli P
    Circulation; 2001 Feb; 103(8):1083-8. PubMed ID: 11222470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between C-reactive protein levels and N-terminal pro-B-type natriuretic peptide in pre-dialysis patients.
    Ortega O; Gallar P; Muñoz M; Rodríguez I; Carreño A; Ortiz M; Molina A; Oliet A; Lozano L; Vigil A
    Nephron Clin Pract; 2004; 97(4):c125-30. PubMed ID: 15331941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of N-terminal pro-B-type natriuretic peptide levels in predicting residual myocardial ischemia in patients with ST elevation acute myocardial infarction.
    Sarullo FM; Gristina T; Brusca I; Serio G; Taormina A; La Chiusa SM; Castello A; Borruso E; Paterna S; Di Pasquale P
    Minerva Cardioangiol; 2007 Apr; 55(2):149-55. PubMed ID: 17342035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial.
    González-Espinoza L; Rojas-Campos E; Medina-Pérez M; Peña-Quintero P; Gómez-Navarro B; Cueto-Manzano AM
    Nephrol Dial Transplant; 2012 May; 27(5):2023-8. PubMed ID: 21968012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy.
    Kurum T; Tatli E; Yuksel M
    Tex Heart Inst J; 2007; 34(1):52-9. PubMed ID: 17420794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different characteristics of chronic heart failure (CHF) in elderly diabetics and non-diabetics.
    Romeo R; Scalisi C; Tafuri L; Romeo A; Maugeri D; Sorace R
    Arch Gerontol Geriatr; 2010; 50(1):101-4. PubMed ID: 19371958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.
    Sola S; Mir MQ; Lerakis S; Tandon N; Khan BV
    J Am Coll Cardiol; 2006 Jan; 47(2):332-7. PubMed ID: 16412856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial.
    Lauterbach R; Pawlik D; Kowalczyk D; Ksycínski W; Helwich E; Zembala M
    Crit Care Med; 1999 Apr; 27(4):807-14. PubMed ID: 10321674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides.
    Foote RS; Pearlman JD; Siegel AH; Yeo KT
    J Am Coll Cardiol; 2004 Nov; 44(10):1980-7. PubMed ID: 15542280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia.
    Sabatine MS; Morrow DA; de Lemos JA; Omland T; Desai MY; Tanasijevic M; Hall C; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2004 Nov; 44(10):1988-95. PubMed ID: 15542281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.
    Richards M; Nicholls MG; Espiner EA; Lainchbury JG; Troughton RW; Elliott J; Frampton CM; Crozier IG; Yandle TG; Doughty R; MacMahon S; Sharpe N; ;
    J Am Coll Cardiol; 2006 Jan; 47(1):52-60. PubMed ID: 16386664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
    Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.
    Di Napoli P; Di Giovanni P; Gaeta MA; D'Apolito G; Barsotti A
    Am Heart J; 2007 Sep; 154(3):602.e1-5. PubMed ID: 17719313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal prohormone brain natriuretic peptide as a marker for detecting low functional class patients and candidates for cardiac transplantation: linear correlation with exercise tolerance.
    Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
    J Heart Lung Transplant; 2007 May; 26(5):516-21. PubMed ID: 17449423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.